Article
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
The New England journal of medicine - 3 Sept 2015
Tefferi Ayalew, Lasho Terra L, Begna Kebede H, Patnaik Mrinal M, Zblewski Darci L, Finke Christy M, Laborde Rebecca R, Wassie Emnet, Schimek Lauren, Hanson Curtis A, Gangat Naseema, Wang Xiaolin, Pardanani Animesh
Abstract excerpt
BACKGROUND: Current drugs for myeloproliferative neoplasm-associated myelofibrosis, including Janus kinase (JAK) inhibitors, do not induce complete or partial remissions. Imetelstat is a 13-mer lipid-conjugated oligonucleotide that targets the RNA template of human telomerase reverse transcriptase. METHODS: We sought to obtain preliminary information on the therapeutic activity and safety of imetelstat in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.